About Exosome Diagnostics
Exosome Diagnostics is a Healthcare company based in Boston (United States) founded in 2008, and was acquired by Bio-Techne in June 2018. Blood-based cancer diagnostics are developed for patient stratification and monitoring. Exosome Diagnostics has raised $118.77 million across 7 funding rounds from investors including Qiagen, Bio-Techne and Forbion. The company has 51 employees. Exosome Diagnostics offers products and services including ExoDx Prostate Test and At-Home Collection Kit. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its legal entity is Exosome Diagnostics, Inc. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Exosome Diagnostics was founded in 2008 in Boston, United States, within the biotechnology sector. Blood-based molecular diagnostics for cancer are developed, focusing on patient stratification and disease monitoring. The ExoDx Prostate test is utilized to extract exosomes from bodily fluids, where disease-specific nucleic acids shed by solid tumors are analyzed. Key genes and mutations associated with prostate cancer are detected through this process. Operations center on advancing non-invasive diagnostic tools.
- Headquarters Boston, United States
- Employees 51
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website exosomedx.com
- Social LinkedIn X
- Acquired by Bio-Techne (Jun 2018)
- Legal Name Exosome Diagnostics, Inc.
- Total Equity Funding$118.77M (USD)
in 7 rounds
- Latest Funding Round$30.29M (USD), Series C
Jul 2017
- InvestorsQiagen
& 8 more
- Employee Count51
- Acquired byBio-Techne
(Jun 2018)
Products & Services of Exosome Diagnostics
Exosome Diagnostics offers a comprehensive portfolio of products and services, including ExoDx Prostate Test and At-Home Collection Kit.
Non-invasive urine-based assay for assessing prostate cancer risk and guiding biopsies.
Enables remote sample collection for prostate cancer testing and risk evaluation.
Funding Insights of Exosome Diagnostics
Exosome Diagnostics has successfully raised a total of $118.77M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $30.29 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $118.77M
- Total Rounds 7
- Last Round Series C — $30.29M
- First Round $20M
(May 2010)
- Investors Count 8
All 7 funding rounds of Exosome Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $30.29M | Series C | – | Forbion, Tiger Advisors | |
| Jan 2016 | $15.3M | Series B | – | – | – |
| Sep 2015 | $17.6M | Series B | – | Arcus Ventures, CD-Venture | – |
| Jun 2015 | $1.48M | Series B | – | – | – |
| Mar 2014 | $27.09M | Series B | – | Qiagen, Arcus Ventures | |
| Aug 2013 | $7M | Series A | – | – | – |
| May 2010 | $20M | Series A | – | NGN Capital, Forbion | – |
9 investors in total: 9 institutional.
Investors in Exosome Diagnostics
Exosome Diagnostics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiagen, Bio-Techne and Forbion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
NGN Capital is engaged in venture capital investments. | ngncapital.com | New York, United States | ||
Arcus Ventures is focused on investing in oncology companies. | arcusventures.com | New York, United States | ||
Investments are made by CD-Venture in early-stage life sciences startups. | cd-venture.com | Heidelberg, Germany | ||
Venture capital is provided to innovative startups by b2venture. | b2venture.vc | St. Gallen, Switzerland | ||
Offers real estate investment and property management solutions. | 1999 | blueridgecapital.com | Atlanta, United States | |
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany | |
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States | |
| tigeradvisors.com |
Investor details for Exosome Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exosome Diagnostics
29 people are tracked at Exosome Diagnostics (1 in leadership, 28 in team); the tracked headcount is 51.
| Name | Role | Group |
|---|---|---|
Hilary Graham Ph.D. | Director, Product Marketing Management | Leadership |
Joshua Merryman | Northwest Account Executive | Team |
Benjamin Sawicki | Senior Research Associate | Team |
Chelsea S. | Senior Account Executive | Team |
Emily Mitsock | Project Manager | Team |
Dan Baughman | Regional Sales Manager | Team |
Matthew Dindinger | Manager, LIMS And Automation | Team |
Johan Skog | Consultant | Team |
Kelli Neary | Senior Accout Representative | Team |
Yang Yang | Senior Scientist | Team |
Bolade Olambiwonnu | Account Executive | Team |
Joseph Wiggins | Account Executive | Team |
Nancy Donovan | Senior Account Executive | Team |
Michelle Jreige Alchalouhy | Medical Laboratory Technician | Team |
Kaitlyn Xavier | Senior Account Executive | Team |
Lorinda Hedstrom | Account Executive | Team |
Brian Raifsnider | Regional Sales Manager | Team |
Katelyn Silk | Supervisor, Client Services | Team |
Katherine Towey | Advanced Molecular Technologist | Team |
John Lagorio | Senior Laboratory Technologist | Team |
9 more people are available in the full profile.
Complete people profiles for Exosome Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Exosome Diagnostics
4 dated milestones of Exosome Diagnostics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Exosome Diagnostics is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series C, of $30.3M.
- Exit Acquired by Bio-Techne.
Competitors of Exosome Diagnostics
Exosome Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Exosome Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Exosome Diagnostics
The website of Exosome Diagnostics (exosomedx.com) receives about 9.4K visits a month and ranks #2,686,224 among all websites worldwide, #3,647 in Biotechnology and Pharmaceuticals.
- Monthly visits9.4K
▲ 22.4% vs previous month
- Unique visitors3.6K
per month
- Global rank#2,686,224
among all websites
- Category rank#3,647
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.8
- Average visit1 min 04 sec
- DevicesDesktop 56% · Mobile 44%
Websites whose visitors overlap most with Exosome Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
| zytovision.com | 87% | 1.8K | #5,562,051 | View details | |
triconference.com | triconference.com | 87% | #1,678,419 | – | |
| roche-australia.com | 87% | 680.7K | #4,116,011 | View details | |
americanprostatecenters.com | americanprostatecenters.com | 66% | #1,170,707 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Exosome Diagnostics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Exosome Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exosome Diagnostics
Complete news archive for Exosome Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exosome Diagnostics
Exosome Diagnostics was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Exosome Diagnostics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Exosome Diagnostics is a funded company, having raised a total of $118.77M across 7 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on May 2010.
Exosome Diagnostics has 51 employees.
Exosome Diagnostics was founded in 2008 in Boston, United States, within the biotechnology sector. Blood-based molecular diagnostics for cancer are developed, focusing on patient stratification and disease monitoring. The ExoDx Prostate test is utilized to extract exosomes from bodily fluids, where disease-specific nucleic acids shed by solid tumors are analyzed. Key genes and mutations associated with prostate cancer are detected through this process. Operations center on advancing non-invasive diagnostic tools.
Exosome Diagnostics's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Exosome Diagnostics offers ExoDx Prostate Test and At-Home Collection Kit.
Exosome Diagnostics has 9 investors. Key investors include Qiagen, Bio-Techne, Forbion, Tiger Advisors, and Blue Ridge Capital.
Exosome Diagnostics operates through Exosome Diagnostics, Inc..
Yes. Exosome Diagnostics was acquired by Bio-Techne in June 2018.